Business Context and Reporting Period
This Form 6-K filing covers the month of April 2019 for Prana Biotechnology Limited (now Alterity Therapeutics Limited), a foreign private issuer based in Melbourne, Australia. The primary purpose of this report is to announce a change of company name following shareholder approval at a General Meeting held on April 5, 2019.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate announcement regarding a name change and does not contain financial statements or performance metrics.
Material Changes
- Company Name Change: The registrant has officially changed its name from "Prana Biotechnology Limited" to "Alterity Therapeutics Limited."
- Regulatory Processing: The name change was processed by the Australian Securities and Investments Commission (ASIC).
- Ticker Symbols: The company anticipates the announcement of new ticker codes ASX: ATH and Nasdaq: ATHE shortly.
Outlook, Risks, and Management Commentary
Business Focus: Alterity Therapeutics is developing PBT434, a small molecule designed to inhibit the aggregation of pathological proteins (alpha-synuclein and tau) implicated in neurodegeneration. The drug aims to treat atypical parkinsonism, including Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP), by restoring normal iron balance in the brain.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include:
- Difficulties or delays in financing, development, testing, regulatory approval, production, and marketing.
- Unexpected adverse side effects or inadequate therapeutic efficacy of PBT434.
- Uncertainty regarding patent protection and intellectual property rights.
Key Facts for Investor Verification
- Confirm the official listing of new ticker symbols (ASX: ATH, Nasdaq: ATHE) on respective exchanges.
- Verify the status of clinical trials for the lead candidate, PBT434, in subsequent filings.
- Review the most recent Form 20-F for detailed financial position and risk factors not included in this announcement.